Log in to search using one of your social media accounts:

 

The impact of the latest echocardiographic chamber quantification recommendations on the prediction of left atrial appendage thrombus presence by transthoracic echocardiography.

CONCLUSIONS: Differentiation between normal and abnormal value enhanced the diagnostic meaning of LAVi in the aspect of higher LAAT risk. LVEF reclassification had no significant influence. PMID: 28799449 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research

Related Links:

A 40-something presented with palpitations and had a regular pulse at 170.Here is his 12-lead ECG:The computer reads supraventricular tachycardia.What is it?It is atrial flutter with 2:1 conduction. It is not PSVT and not sinus.There are clear flutter waves in lead II across the bottom. In V1, there are upright waves that appear to be P-waves but are not: they are atrial waves and it is typical for atrial flutter waves to be upright in V1, whereas sinus P-waves are biphasic in V1.The flutter rate is relatively fast at 334, such that the ventricular rate is 167 (one half the atrial rate).As easy as it may seem to ...
Source: Dr. Smith's ECG Blog - Category: Cardiology Authors: Source Type: blogs
Conclusions The efficacy advantage of DCS over BMS up to 2 years appears confirmed in patients on long-term OAC. Despite the very short course of dual antiplatelet therapy, both the DCS and BMS groups experienced similarly high rates of major bleeding. (A Randomized Clinical Evaluation of the BioFreedom™ Stent [Leaders Free]; NCT01623180)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - Category: Cardiology Authors: Tags: Coronary: Focus on Antithrombotic Drugs Source Type: research
Patients with end-stage renal disease (ESRD) on maintenance hemodialysis (HD) are at risk for occurrence of vascular access thrombosis and venous thromboembolism (VTE). Understanding the extent of these complications and identifying risk factors can help improve management strategies.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Full Length Article Source Type: research
This study describes a cohort of patients with FXa inhibitor-associated life-threatening bleeding events, their clinical characteristics, interventions and outcomes.
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Source Type: research
ConclusionWhen compared with warfarin, dabigatran was associated with a comparable incidence of first hospital admission but a higher risk of 30‐day redmission with respect to bleeding. Close early monitoring of patients initiated on dabigatran following hospital discharge for bleeding is warranted.
Source: Journal of Thrombosis and Haemostasis - Category: Hematology Authors: Tags: Original Article Source Type: research
Publication date: March 2018 Source:Advances in Medical Sciences, Volume 63, Issue 1 Author(s): Ewelina Michniewicz, Elżbieta Mlodawska, Paulina Lopatowska, Anna Tomaszuk-Kazberuk, Jolanta Malyszko Coronary artery disease (CAD) is the most common cardiovascular disease while atrial fibrillation (AF) is the most common cardiac arrhythmia. Both diseases share associated risk factors – hypertension, diabetes mellitus, sleep apnea, obesity and smoking. Moreover, inflammation plays a causative role in both diseases. The prevalence of CAD in patients with AF is from 17% to 46.5% while the prevalence of AF among patients ...
Source: Advances in Medical Sciences - Category: Biomedical Science Source Type: research
ConclusionsOur case report adds to the evidence that idarucizumab administration is safe in the setting of patients with atrial fibrillation treated with dabigatran who develop acute ischemic stroke requiring thrombolysis.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Prevention of ischaemic stroke has long been central to the management of patients with atrial fibrillation (AF), historically relying on the use of vitamin K antagonists (VKAs) or antiplatelet agents depending on the risk of thromboembolism. Difficulties associated with maintaining VKAs in therapeutic range and the perceived risk of bleeding have been highlighted as reasons to withhold oral anticoagulation (OAC) and these issues have partly been addressed by the introduction of non-vitamin K antagonist oral anticoagulants (NOACs).
Source: Radcliffe Cardiology - Category: Cardiology Authors: Source Type: research
Abstract Coronary artery disease (CAD) is the most common cardiovascular disease while atrial fibrillation (AF) is the most common cardiac arrhythmia. Both diseases share associated risk factors - hypertension, diabetes mellitus, sleep apnea, obesity and smoking. Moreover, inflammation plays a causative role in both diseases. The prevalence of CAD in patients with AF is from 17% to 46.5% while the prevalence of AF among patients with CAD is low and it is estimated from 0.2% to 5%. AF is a well-established factor of poor short- and long-term prognosis in patients with acute myocardial infarction (AMI) and is associ...
Source: Advances in Medical Sciences - Category: Biomedical Science Authors: Tags: Adv Med Sci Source Type: research
CONCLUSIONS: Despite similar exposure to both drugs, rivaroxaban 20 mg once daily was associated with greater and more sustained inhibition of thrombin generation than apixaban 5 mg twice daily. Sensitive prothrombin time and activated partial thromboplastin time assays can be used to estimate the anticoagulant effects of rivaroxaban. This article is protected by copyright. All rights reserved. PMID: 28805299 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: J Thromb Haemost Source Type: research
More News: Atrial Fibrillation | Cardiology | Databases & Libraries | Heart | Study | Thrombosis